PaxVax, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Redwood CA United States (2006)
Status: Acquired by Emergent BioSolutions (2018)

Organization Overview

First Clinical Trial
2009
NCT01006798
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

PaxVax, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoviridae Infections (Phase 1)

Anthrax (Phase 1)

Chikungunya Fever (Phase 2)

Cholera (Phase 4)

Influenza, Human (Phase 1)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial APIs: 13